Gillian Dohrn

Gillian Dohrn

Seattle, Washington, USA

Sana Biotechnology Opens $80M Manufacturing Facility in Bothell to Scale Cancer and Gene Therapy Production

Sana Biotechnology inaugurated its new 80,000 square-foot manufacturing facility in Bothell, Washington, dedicated to producing its proprietary cancer drug program and future therapies. The company, known for its gene-editing technology and multiple drugs in human trials including for cancer, autoimmune diseases, and type 1 diabetes, sees this expansion as a key step in advancing scalable cell and gene therapies.

Bonum Therapeutics Moves to New Seattle Offices, Plans Team Expansion in Cancer Immunotherapy Push

Seattle biotech startup Bonum Therapeutics is relocating to a new office at 1150 Eastlake Ave E and plans to double its 31-person team as it pursues developing safer immunotherapy cancer drugs. Founded by CEO John Mulligan after a $250 million acquisition of his previous company Good Therapeutics by Roche, Bonum recently raised $93 million to fund its expansion.